Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over.
Cirrhosis
Elderly patients
Genotype 2
Hepatitis C virus
Ribavirin
Sofosbuvir
Journal
World journal of hepatology
ISSN: 1948-5182
Titre abrégé: World J Hepatol
Pays: United States
ID NLM: 101532469
Informations de publication
Date de publication:
27 Sep 2020
27 Sep 2020
Historique:
received:
10
04
2020
revised:
12
07
2020
accepted:
26
07
2020
entrez:
9
10
2020
pubmed:
10
10
2020
medline:
10
10
2020
Statut:
ppublish
Résumé
Although clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus, patients ≥ 75-years-old have not been included in previous clinical trials. To evaluate the real-world safety and efficacy of sofosbuvir plus ribavirin for elderly patients (≥ 75-years-old) compared to nonelderly patients, we conducted a post-marketing prospective cohort study. We treated 265 patients with genotype 2 hepatitis C virus using standard approved doses of sofosbuvir (400 mg/d) plus ribavirin adjusted by body weight, administered orally for 12 wk. Sustained virological response rates for the overall cohort, patients < 65-years-old, ≥ 65-years-old but < 75-years-old, and ≥ 75-years-old were 97% (258/265), 98% (93/95), 97% (84/87), and 98% (81/83), respectively ( Although ribavirin dose reduction or interruption was required with advanced age, sofosbuvir plus ribavirin appears tolerable and highly effective even in patients ≥ 75-years-old.
Sections du résumé
BACKGROUND
BACKGROUND
Although clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus, patients ≥ 75-years-old have not been included in previous clinical trials.
AIM
OBJECTIVE
To evaluate the real-world safety and efficacy of sofosbuvir plus ribavirin for elderly patients (≥ 75-years-old) compared to nonelderly patients, we conducted a post-marketing prospective cohort study.
METHODS
METHODS
We treated 265 patients with genotype 2 hepatitis C virus using standard approved doses of sofosbuvir (400 mg/d) plus ribavirin adjusted by body weight, administered orally for 12 wk.
RESULTS
RESULTS
Sustained virological response rates for the overall cohort, patients < 65-years-old, ≥ 65-years-old but < 75-years-old, and ≥ 75-years-old were 97% (258/265), 98% (93/95), 97% (84/87), and 98% (81/83), respectively (
CONCLUSION
CONCLUSIONS
Although ribavirin dose reduction or interruption was required with advanced age, sofosbuvir plus ribavirin appears tolerable and highly effective even in patients ≥ 75-years-old.
Identifiants
pubmed: 33033572
doi: 10.4254/wjh.v12.i9.672
pmc: PMC7522558
doi:
Types de publication
Journal Article
Langues
eng
Pagination
672-684Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Références
Hepatology. 1997 Aug;26(2):473-7
pubmed: 9252161
J Viral Hepat. 2014 Nov;21(11):762-8
pubmed: 25196837
N Engl J Med. 2014 May 22;370(21):1993-2001
pubmed: 24795201
N Engl J Med. 2013 May 16;368(20):1878-87
pubmed: 23607594
Liver Int. 2017 Feb;37(2):205-211
pubmed: 27428297
Am J Gastroenterol. 2004 May;99(5):860-5
pubmed: 15128351
Hepatol Int. 2016 Sep;10(5):702-26
pubmed: 27130427
Liver Int. 2018 Sep;38(9):1552-1561
pubmed: 29297980
Ann Pharmacother. 2014 May 8;48(8):1019-1029
pubmed: 24811396
Gut. 2017 Oct;66(10):1844-1852
pubmed: 27418632
Hepatology. 2015 Sep;62(3):932-54
pubmed: 26111063
Dig Dis. 2016;34(6):632-639
pubmed: 27750230
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
Gut Liver. 2016 Jul 16;10(4):617-23
pubmed: 26601828
Intern Med. 2019 Feb 15;58(4):477-485
pubmed: 30333396
Antiviral Res. 2016 Dec;136:37-44
pubmed: 27789224
J Hepatol. 2014 Apr;60(4):741-7
pubmed: 24333184
N Engl J Med. 2013 May 16;368(20):1867-77
pubmed: 23607593
Dig Liver Dis. 2017 Sep;49(9):1029-1035
pubmed: 28499694
BMJ Open Gastroenterol. 2018 Jun 29;5(1):e000207
pubmed: 30002863
J Hepatol. 1996 Nov;25(5):591-8
pubmed: 8938532
Hepatol Res. 2019 Mar;49(3):264-270
pubmed: 30171740
Infect Drug Resist. 2019 Sep 19;12:2987-3015
pubmed: 31571951
Hepatol Res. 2018 Jun;48(7):529-538
pubmed: 29316051
Hepatology. 2018 Feb;67(2):505-513
pubmed: 28865152
J Gastroenterol. 2011 Apr;46(4):536-44
pubmed: 21132575